Plague - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Plague - Pipeline Review, H2 2014', provides an overview of the Plague's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Plague - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Plague pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Plague - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Plague pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Plague Overview 7 Therapeutics Development 8 Pipeline Products for Plague - Overview 8 Pipeline Products for Plague - Comparative Analysis 9 Plague - Therapeutics under Development by Companies 10 Plague - Therapeutics under Investigation by Universities/Institutes 11 Plague - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Plague - Products under Development by Companies 15 Plague - Products under Investigation by Universities/Institutes 16 Plague - Companies Involved in Therapeutics Development 17 Aradigm Corporation 17 Cellceutix Corporation 18 iBio, Inc. 19 Mucosis B.V. 20 Summit Corporation plc 21 Syntiron LLC 22 Plague - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Combination Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 anthrax + plague vaccine - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ciprofloxacin hydrochloride - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 plague vaccine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Plague Vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 plague vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 plague vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 plague vaccine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 plague vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 plague vaccine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 PMX-30016 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecules to Inhibit PTP for Plague - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 SMT-15000 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 yersinia pestis vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Yersinia pestis vaccine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Plague - Recent Pipeline Updates 48 Plague - Dormant Projects 49 Plague - Discontinued Products 50 Plague - Product Development Milestones 51 Featured News & Press Releases 51 Jun 05, 2008: Computer Sciences Corporation's DynPort Vaccine Company To Continue Plague Vaccine Development 51 Nov 18, 2005: Computer Sciences Corporation's DynPort Vaccine Company Reaches Milestone In Plague Vaccine Clinical Trial 51 Jan 10, 2005: Computer Sciences Corporation's DynPort Vaccine Company Enters Clinical Trial For Plague Vaccine Candidate 51 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 54 Disclaimer 54
List of Tables Number of Products under Development for Plague, H2 2014 8 Number of Products under Development for Plague - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Comparative Analysis by Unknown Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Plague - Pipeline by Aradigm Corporation, H2 2014 17 Plague - Pipeline by Cellceutix Corporation, H2 2014 18 Plague - Pipeline by iBio, Inc., H2 2014 19 Plague - Pipeline by Mucosis B.V., H2 2014 20 Plague - Pipeline by Summit Corporation plc, H2 2014 21 Plague - Pipeline by Syntiron LLC, H2 2014 22 Assessment by Monotherapy Products, H2 2014 23 Assessment by Combination Products, H2 2014 24 Number of Products by Stage and Target, H2 2014 26 Number of Products by Stage and Mechanism of Action, H2 2014 28 Number of Products by Stage and Route of Administration, H2 2014 30 Number of Products by Stage and Molecule Type, H2 2014 32 Plague Therapeutics - Recent Pipeline Updates, H2 2014 48 Plague - Dormant Projects, H2 2014 49 Plague - Discontinued Products, H2 2014 50
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.